Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to sift through pages of clinical jargon just to see how LINZESS sales or IBS-C trial costs impact Ironwood Pharmaceuticals? Biopharma filings can bury crucial details on royalty rates, FDA milestones, and pipeline spend. That’s why Stock Titan places every Ironwood Pharmaceuticals SEC filing in one organised hub and layers it with AI-powered summaries that translate complex disclosures into plain language.
Want the latest numbers? Our system pulls the Ironwood Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR. Curious about leadership moves? We stream Ironwood Pharmaceuticals Form 4 insider transactions real-time, so you can monitor executive stock activity alongside LINZESS performance. Each document—whether a 10-K annual report, 8-K clinical update, or DEF 14A proxy—is paired with concise explanations that answer everyday questions like “How is Ironwood funding its Phase III GI program?� or “What does the latest 8-K material event mean for revenue guidance?�
Here’s what you’ll uncover faster than ever:
- Ironwood Pharmaceuticals annual report 10-K simplified to reveal GI market share, royalty waterfalls, and risk factors.
- Ironwood Pharmaceuticals insider trading Form 4 transactions and alerts on option exercises.
- Board and pay insights inside the Ironwood Pharmaceuticals proxy statement executive compensation filing.
- Instant context for every Ironwood Pharmaceuticals 8-K material events explained by AI.
- Side-by-side Ironwood Pharmaceuticals earnings report filing analysis that tracks R&D burn against pipeline milestones.
Stop guessing and start understanding Ironwood Pharmaceuticals SEC documents with AI. Stock Titan’s expert engine converts dense biotech paperwork into clear takeaways—so you can focus on decisions, not decoding.
Ironwood Pharmaceuticals reported a profitable quarter but a loss for the first half of 2025. For the three months ended June 30, 2025 the company recorded $23.6 million of net income (basic EPS $0.15), driven by collaborative arrangements revenue of $85.2 million and reduced operating costs. For the six months ended June 30, 2025, revenue from collaborative arrangements was $126.4 million versus $169.3 million a year earlier, and the company recorded a $13.8 million net loss for the period.
The balance sheet shows $92.9 million of cash and cash equivalents and accounts receivable of $86.2 million, largely due from AbbVie. Current liabilities increased sharply to $232.5 million primarily because the $200.0 million 2026 Convertible Notes are presented, in part, as a current obligation (net carrying amount $199.3 million) and these notes mature on June 15, 2026. Management states available liquidity and borrowing capacity are sufficient to meet operations for at least the next 12 months.
This Form 144 notifies a proposed sale of 8,281 shares of Ironwood Pharmaceuticals, Inc. Class A common stock with an aggregate market value of $7,287.28. The sale is listed to occur through E Trade Securities LLC on the Nasdaq exchange on 08/11/2025. The securities were originally acquired as a Restricted Stock Unit award under the issuer's 2019 Equity Incentive Plan on 08/02/2021, with 19,973 units shown as acquired on that date.
The filing reports 161,819,848 shares outstanding, and indicates no securities sold in the past three months by the person for whose account the sale is filed. The notice includes the filer's representation that they do not know of any undisclosed material adverse information regarding the issuer.
Ironwood Pharmaceuticals filed a Form 144 reporting a proposed sale of 1,351 shares of Class A common stock on Nasdaq, with an aggregate market value of $1,188.88. The sale is listed with an approximate sale date of 08/11/2025. The filer acquired 4,000 shares as a Restricted Stock Unit award on 08/16/2023, and no securities of the issuer were reported sold by the filer in the past three months.
The filing includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer. The shares to be sold amount to approximately 0.000835% of the 161,819,848 shares outstanding, indicating a very small proposed disposition relative to the company’s market capitalization.
Ironwood Pharmaceuticals Form 144 reports that Tammi Gaskins proposes to sell 1,406 shares of Class A common stock on 08/11/2025 through E Trade (Nasdaq), with an aggregate market value of $1,237.28. The filing states these shares were acquired as 4,000 restricted stock units granted on 08/16/2023.
The notice also discloses a prior sale of 2,563 shares on 05/16/2025 for gross proceeds of $1,486.54. The filer affirms they do not possess undisclosed material adverse information.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
